DCT

1:26-cv-01094

Aziende Chimiche Riunite Angelini Francesco Acraf Spa v. Oxford Pharma LLC

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-01094, D. Del., 08/28/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant is a Delaware corporation and has purposefully availed itself of the jurisdiction by, among other things, applying to the FDA for approval to market its generic drugs in Delaware.
  • Core Dispute: Plaintiff alleges that Defendant's filing of a supplemental Abbreviated New Drug Application (ANDA) for a generic version of the antidepressant DESYREL® constitutes an act of infringement of a patent related to a highly purified form of the active ingredient, trazodone hydrochloride.
  • Technical Context: The technology relates to pharmaceutical chemistry, specifically a purification process that reduces the level of potentially genotoxic impurities in the active pharmaceutical ingredient trazodone hydrochloride.
  • Key Procedural History: The lawsuit is a Hatch-Waxman Act case, triggered by Defendant's filing of a supplemental ANDA with the FDA. As part of that filing, Defendant submitted a Paragraph IV certification alleging that Plaintiff's patent is invalid or will not be infringed by its proposed generic product, which prompted this infringement action.

Case Timeline

Date Event
2007-08-03 '893 Patent Priority Date
2012-03-13 '893 Patent Issued
2026-07-15 Oxford Notice Letter Sent to Plaintiff
2026-07-16 Oxford Notice Letter Delivered to Plaintiff's Counsel
2026-08-28 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,133,893 - Trazodone and Trazodone Hydrochloride in Purified Form

  • Patent Identification: U.S. Patent No. 8,133,893, issued March 13, 2012.

The Invention Explained

  • Problem Addressed: The patent describes that conventional synthesis processes for the antidepressant drug trazodone can result in the final product containing small amounts of impurities known as "alkylating substances" ('893 Patent, col. 4:10-18). These substances are noted as having "proven or suspected genotoxicity," making their presence undesirable in a pharmaceutical product ('893 Patent, col. 4:17-18; '893 Patent, col. 6:53-56).
  • The Patented Solution: The invention provides a purified form of trazodone (or its hydrochloride salt) and a process to achieve it ('893 Patent, abstract). The process involves washing a solution of trazodone with a basic aqueous solution, which removes the undesirable alkylating substances to a very low level ('893 Patent, col. 4:29-51). The resulting product is a composition of trazodone hydrochloride containing less than 15 parts per million (ppm) of a specific list of these impurities ('893 Patent, col. 7:27-34).
  • Technical Importance: Achieving high purity and minimizing genotoxic impurities is a critical objective in pharmaceutical manufacturing to meet modern drug safety and regulatory standards.

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims, including at least claim 1 (Compl. ¶32; Compl. ¶36; Compl. ¶37).
  • Independent Claim 1 recites:
    • Trazodone or trazodone hydrochloride,
    • wherein alkylating substances are present in a total amount which is less than 15 ppm,
    • and said alkylating substances are selected from a specified group of chemical compounds including 2,2-dichloroethylamine and 1-bromo-3-chloro-propane, among others.
  • The complaint does not specifically identify any dependent claims for assertion.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant's proposed generic Trazodone Hydrochloride tablets in 25 mg, 75 mg, and 100 mg doses, for which it seeks FDA approval via supplemental ANDA No. 072193 (Compl. ¶1; Compl. ¶3). This is referred to as "Oxford's ANDA Product" (Compl. ¶3).

Functionality and Market Context

The product is a generic version of DESYREL®, a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (Compl. ¶2). The complaint alleges that Oxford's product is bioequivalent to DESYREL® (Compl. ¶5). The filing of the ANDA is alleged to be an act of infringement under 35 U.S.C. § 271(e)(2)(A), as it seeks approval to market the generic product before the expiration of the '893 patent (Compl. ¶34). No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint alleges that the submission of the supplemental ANDA for the purpose of obtaining approval to market Oxford's ANDA Product is a statutory act of infringement (Compl. ¶34). The infringement theory is that the product described in the ANDA, if commercially manufactured and sold, would meet the limitations of the asserted claims of the '893 Patent (Compl. ¶36).

'893 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
Trazodone or trazodone hydrochloride, Oxford's ANDA Product is identified as a generic version of Trazodone Hydrochloride tablets. ¶3 col. 7:22-23
wherein alkylating substances are present in a total amount which is less than 15 ppm The complaint alleges that Oxford's ANDA Product would infringe one or more claims, including claim 1, implying it will meet this purity limitation. This is predicated on the allegation that Oxford's product is a generic version of DESYREL®, which is covered by the patent. ¶26; ¶36 col. 7:24-27
and said alkylating substances are selected from the group consisting of 2,2-dichloroethylamine, 1-bromo-3-chloro-propane, N-(3-chlorophenyl)-N'-(3-chloropropyl)-piperazine, 2-(3-chloropropyl)-s-triazolo-[4,3-a]-pyridin-3-one, 3-chloro-N,N'-dichloroethyl-aniline, 2-{3-[bis-(2-chloroethyl)-amino]-propyl}-2H-[1,2,4]-triazolo[4,3-a]pyridin-3-one, 2,2-dibromoethylamine, 1,3-dichloropropane and a mixture thereof. This list defines the specific impurities to be measured. The complaint alleges the ANDA product infringes the claim containing this limitation, though it does not provide specific data on the impurity profile. ¶24; ¶36 col. 7:25-34
  • Identified Points of Contention:
    • Factual Question: A central question will be factual: does the generic trazodone hydrochloride product described in Oxford's ANDA actually meet the "less than 15 ppm" purity limitation for the specific list of "alkylating substances" defined in claim 1? The defendant's Paragraph IV certification of non-infringement suggests it will argue its product falls outside this claimed purity level (Compl. ¶6).
    • Evidentiary Question: The complaint does not contain test results demonstrating the impurity profile of Oxford's proposed product. The analysis will depend on evidence obtained during discovery regarding the exact composition and manufacturing process of the product described in the ANDA.

V. Key Claim Terms for Construction

  • The Term: "alkylating substances"
  • Context and Importance: The entire basis of the invention is the reduction of these specific impurities. The infringement analysis hinges entirely on identifying and quantifying this defined group of "alkylating substances" in the accused product to determine if their "total amount" is below 15 ppm. Practitioners may focus on this term because the scope and method of measurement will be determinative of infringement.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party could argue the term's scope is strictly and exhaustively defined by the explicit list provided in the claim itself ("selected from the group consisting of...") ('893 Patent, col. 7:27-34). This suggests any substance on the list must be counted toward the 15 ppm total, without further qualification.
    • Evidence for a Narrower Interpretation: The specification repeatedly characterizes these substances by their function as having "proven or suspected genotoxicity" ('893 Patent, col. 4:17-18). A party might argue that the analytical methods detailed in the specification for detecting these substances (e.g., the spectrophotometry and chromatography methods) are definitional for how the "total amount" should be calculated ('893 Patent, col. 10:59-12:40). This could raise disputes over detection limits and which specific analytical techniques are appropriate for establishing infringement.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both contributory and induced infringement. The basis for inducement is that Oxford knows its product and labeling will cause its customers, distributors, and others to directly infringe ('893 Patent, col. 8:3-8). The basis for contributory infringement is that Oxford's product is especially made for an infringing use and is not a staple article of commerce suitable for substantial noninfringing use (Compl. ¶39).
  • Willful Infringement: The complaint alleges that Oxford acted with "full knowledge of the '893 patent and without a reasonable basis" for its non-infringement position (Compl. ¶44). This allegation is supported by Oxford's notice letter, which demonstrates pre-suit knowledge of the patent (Compl. ¶3).

VII. Analyst's Conclusion: Key Questions for the Case

This Hatch-Waxman dispute appears to center on a question of pharmaceutical purity. The outcome will likely depend on the answers to a few central questions:

  1. A Factual Question of Composition: Can the plaintiff demonstrate through discovery that the generic product, as specified in the defendant's ANDA, will necessarily contain a total amount of the specifically listed "alkylating substances" below the 15 ppm threshold of claim 1? Conversely, can the defendant show its product is formulated or manufactured in a way that avoids this purity limitation, thereby validating its non-infringement certification?

  2. A Strategic Question of Invalidity: The defendant has certified that the '893 patent is invalid (Compl. ¶6). A key aspect of the case will be the defendant's ability to prove, likely through prior art or other arguments, that the claimed purified composition was not novel or was obvious at the time of the invention.

  3. An Evidentiary Question of Measurement: Should a dispute arise over how to measure the impurities, a critical issue will be whether the analytical methods detailed in the patent specification are merely exemplary or are essential for determining whether the "less than 15 ppm" limitation is met.